drugset
drugset / Trial / NCT03144271

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

NCT03144271 ↗

Phase 1 Completed 58 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability of ascending single s.c. doses of NNC 0113-0217 in healthy male subjects, aiming at establishing the Maximum Tolerated Dose (MTD)

Timeline

Start
2007-06-11
Primary completion
2007-10-08
Completion
2007-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 0.625 ug/kg Subcutaneous
Subject Semaglutide Peptide 1.25 ug/kg Subcutaneous
Subject Semaglutide Peptide 2.5 ug/kg Subcutaneous
Subject Semaglutide Peptide 5 ug/kg Subcutaneous
Subject Semaglutide Peptide 10 ug/kg Subcutaneous
Subject Semaglutide Peptide 20 ug/kg Subcutaneous
Subject Semaglutide Peptide 40 ug/kg Subcutaneous
Subject Semaglutide Peptide 80 ug/kg Subcutaneous

Indications

type 2 diabetes mellitus